Comprehensively, it can be stated that increasinginfiltration and/or activity of desirable anti-tumor T-cells (effector T-cells)within the tumor microenvironment results in more durable patient response.Identification of new proteins that confer an immunomodulatory response inmalignancy is critically important, in part due to the enormous clinical successesof the checkpoint inhibitors Pembrolizumab (anti-PD-1) and Ipilimumab(anti-CTLA-4)3,4. The gene discussed is CTLA4; the disease is neoplasm.